Q2 FY2024 Earnings
Financial report interval: 2024.03.30 - 2024.06.30
Overview: Seelos Therapeutics(SEEL) the Revenue is 376 K (+11.9%);the EPS is 1.98 (+100.2%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B11.90%
----
----
EPS
1.9782100.23%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf